China SXT Pharmaceuticals (SXTC) Total Non-Current Liabilities (2019 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Total Non-Current Liabilities of $697832.0 for Q1 2026, up 229.66% year-on-year from $211683.0 in Q1 2025, and up 340.93% on a QoQ basis from $158263.0 in Q3 2025.
China SXT Pharmaceuticals (SXTC) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
China SXT Pharmaceuticals (SXTC) has reported Total Non-Current Liabilities for 8 consecutive years, with $697832.0 the latest figure, recorded in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 229.66% year-over-year to $697832.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $697832.0 (up 229.66% YoY) and the FY2026 annual result came in at $697832.0, up 229.66% from the prior year.
- Total Non-Current Liabilities climbed to $697832.0 in Q1 2026 per SXTC's latest filing, from $158263.0 in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for SXTC reached as high as $17.0 million in Q1 2022 and fell as low as $158263.0 in Q3 2025.
- A 5-year average of $2.9 million and a median of $311512.0 in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 270065.16% — and 2023, when it sank 97.85%.
- Year by year, Total Non-Current Liabilities stood at $7.2 million in 2022, then tumbled by 95.66% to $311512.0 in 2023, then dropped by 4.33% to $298011.0 in 2024, then tumbled by 46.89% to $158263.0 in 2025, then surged by 340.93% to $697832.0 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $697832.0, $158263.0, and $211683.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | China SXT Pharmaceuticals | 7.11 Mn | -21.06 Mn | - | 697,832.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 697,832.00 |
| Sep 30, 2025 | 158,263.00 |
| Mar 31, 2025 | 211,683.00 |
| Sep 30, 2024 | 298,011.00 |
| Mar 31, 2024 | 294,667.00 |
| Sep 30, 2023 | 311,512.00 |
| Mar 31, 2023 | 365,823.00 |
| Sep 30, 2022 | 7.18 Mn |
| Mar 31, 2022 | 17.00 Mn |
| Sep 30, 2021 | 8.40 Mn |
| Mar 31, 2021 | 6,292.00 |
| Sep 30, 2020 | 15,213.00 |
| Mar 31, 2020 | 36,511.00 |
| Sep 30, 2019 | 873,282.00 |
| Mar 31, 2019 | 41,706.00 |